Clinical trial
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
NCT00264433 · Adherex Technologies, Inc., Industry · Completed
Key facts
| NCT number | NCT00264433 |
|---|---|
| Title | A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent |
| Official title | An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201) |
| Lead sponsor | Adherex Technologies, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | ADH -1 (Exherin™) |
| First posted | Dec 13, 2005 |
| Last update posted | Aug 6, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: